openPR Logo
Press release

Myotonic Dystrophy Pipeline Drugs Analysis Report, 2024 Updates: FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight | Dyne Therapeutics, Avidity Biosciences, Harmony Biosciences, AMO Pharma, Lupin, AMO Pharma

05-15-2024 08:42 PM CET | Health & Medicine

Press release from: DelveInsight Business Research

Myotonic Dystrophy Pipeline Drugs Analysis Report, 2024

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Myotonic Dystrophy pipeline constitutes 20+ key companies continuously working towards developing 22+ Myotonic Dystrophy treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

"Myotonic Dystrophy Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Myotonic Dystrophy Market.

The Myotonic Dystrophy Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Myotonic Dystrophy Pipeline Report: https://www.delveinsight.com/sample-request/myotonic-dystrophy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Myotonic Dystrophy treatment therapies with a considerable amount of success over the years.
• Myotonic Dystrophy companies working in the treatment market are Design Therapeutics, Enzerna, Juvena Therapeutics, Dyne Therapeutics, Avidity Biosciences, Harmony Biosciences, AMO Pharma, Lupin, AMO Pharma, Dyne Therapeutics, Entrada Therapeutics, and others, are developing therapies for the Myotonic Dystrophy treatment
• Emerging Myotonic Dystrophy therapies in the different phases of clinical trials are- DM1 program, ENZ-001, JUV 161, DYNE-101, AOC 1001, Pitolisant, Tideglusib, Mexiletine, AMO-02, DYNE-101, ENTR-701, and others are expected to have a significant impact on the Myotonic Dystrophy market in the coming years.
• In February 2024, The candidate developed by PepGen for treating myotonic dystrophy type 1 (DM1) has received fast track designation from the US Food and Drug Administration (FDA).
• In November 2023, Arrowhead Pharmaceuticals has filed an application for regulatory approval to initiate a Phase I/IIa clinical study of its investigational RNA interference (RNAi) therapy, ARO-DM1, aimed at potentially treating type 1 myotonic dystrophy (DM1), the most prevalent form of adult-onset muscular dystrophy.
• In September 2023, AMO Pharma Limited, a clinical-stage specialty biopharmaceutical company dedicated to rare childhood-onset neurogenetic disorders with limited or no available treatments, disclosed findings from its REACH-CDM clinical trial evaluating the investigational therapy AMO-02 in children and adolescents with congenital myotonic dystrophy.

Myotonic Dystrophy Overview
Myotonic dystrophy (DM) is a genetic disorder characterized by progressive muscle wasting and weakness. It is the most common form of adult-onset muscular dystrophy. Myotonic dystrophy affects multiple body systems, including skeletal and smooth muscles, the heart, endocrine system, and central nervous system.

Get a Free Sample PDF Report to know more about Myotonic Dystrophy Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/myotonic-dystrophy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Emerging Myotonic Dystrophy Drugs Under Different Phases of Clinical Development Include:
• DM1 program: Design Therapeutics
• ENZ-001: Enzerna
• JUV 161: Juvena Therapeutics
• DYNE-101: Dyne Therapeutics
• AOC 1001: Avidity Biosciences
• Pitolisant: Harmony Biosciences
• Tideglusib: AMO Pharma
• Mexiletine: Lupin
• AMO-02: AMO Pharma
• DYNE-101: Dyne Therapeutics
• ENTR-701: Entrada Therapeutics

Myotonic Dystrophy Route of Administration
Myotonic Dystrophy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical

Myotonic Dystrophy Molecule Type
Myotonic Dystrophy Products have been categorized under various Molecule types, such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Myotonic Dystrophy Pipeline Therapeutics Assessment
• Myotonic Dystrophy Assessment by Product Type
• Myotonic Dystrophy By Stage and Product Type
• Myotonic Dystrophy Assessment by Route of Administration
• Myotonic Dystrophy By Stage and Route of Administration
• Myotonic Dystrophy Assessment by Molecule Type
• Myotonic Dystrophy by Stage and Molecule Type

DelveInsight's Myotonic Dystrophy Report covers around 22+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Myotonic Dystrophy product details are provided in the report. Download the Myotonic Dystrophy pipeline report to learn more about the emerging Myotonic Dystrophy therapies
https://www.delveinsight.com/sample-request/myotonic-dystrophy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key companies in the Myotonic Dystrophy Therapeutics Market include:
Key companies developing therapies for Myotonic Dystrophy are - Lupin, AMO Pharma, Harmony Biosciences, Avidity Biosciences, Dyne Therapeutics, Nexien BioPharma, Locana, Inc., Entrada Therapeutics, Arthex Biotech, NeuBase Therapeutics, NeuBase Therapeutics, Enzerna, Enzerna, Astellas Gene Therapies, Dyne Therapeutics, Pepgen Corporation, Sangamo Therapeutics, Syros Pharmaceuticals, and others.

Myotonic Dystrophy Pipeline Analysis:
The Myotonic Dystrophy pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Myotonic Dystrophy with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Myotonic Dystrophy Treatment.
• Myotonic Dystrophy key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Myotonic Dystrophy Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Myotonic Dystrophy market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Myotonic Dystrophy drugs and therapies
https://www.delveinsight.com/sample-request/myotonic-dystrophy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Myotonic Dystrophy Pipeline Market Drivers
• Technological advancements in Myotonic Dystrophy genomic research, management of multisystem disorder associated with Myotonic Dystrophy are some of the important factors that are fueling the Myotonic Dystrophy Market.

Myotonic Dystrophy Pipeline Market Barriers
• However, lack of Approved therapies, lack of understanding of pathophysiology and mechanisms of DNA instability and other factors are creating obstacles in the Myotonic Dystrophy Market growth.

Scope of Myotonic Dystrophy Pipeline Drug Insight
• Coverage: Global
• Key Myotonic Dystrophy Companies: Design Therapeutics, Enzerna, Juvena Therapeutics, Dyne Therapeutics, Avidity Biosciences, Harmony Biosciences, AMO Pharma, Lupin, AMO Pharma, Dyne Therapeutics, Entrada Therapeutics, and others
• Key Myotonic Dystrophy Therapies: DM1 program, ENZ-001, JUV 161, DYNE-101, AOC 1001, Pitolisant, Tideglusib, Mexiletine, AMO-02, DYNE-101, ENTR-701, and others
• Myotonic Dystrophy Therapeutic Assessment: Myotonic Dystrophy current marketed and Myotonic Dystrophy emerging therapies
• Myotonic Dystrophy Market Dynamics: Myotonic Dystrophy market drivers and Myotonic Dystrophy market barriers

Request for Sample PDF Report for Myotonic Dystrophy Pipeline Assessment and clinical trials
https://www.delveinsight.com/sample-request/myotonic-dystrophy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1. Myotonic Dystrophy Report Introduction
2. Myotonic Dystrophy Executive Summary
3. Myotonic Dystrophy Overview
4. Myotonic Dystrophy- Analytical Perspective In-depth Commercial Assessment
5. Myotonic Dystrophy Pipeline Therapeutics
6. Myotonic Dystrophy Late Stage Products (Phase II/III)
7. Myotonic Dystrophy Mid Stage Products (Phase II)
8. Myotonic Dystrophy Early Stage Products (Phase I)
9. Myotonic Dystrophy Preclinical Stage Products
10. Myotonic Dystrophy Therapeutics Assessment
11. Myotonic Dystrophy Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Myotonic Dystrophy Key Companies
14. Myotonic Dystrophy Key Products
15. Myotonic Dystrophy Unmet Needs
16 . Myotonic Dystrophy Market Drivers and Barriers
17. Myotonic Dystrophy Future Perspectives and Conclusion
18. Myotonic Dystrophy Analyst Views
19. Appendix
20. About DelveInsight

Related Reports:

Myotonic Dystrophy Market https://www.delveinsight.com/report-store/myotonic-dystrophy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Myotonic Dystrophy-Market Insights, Epidemiology, and Market Forecast-2032' report delivers an in-depth understanding of the 7MM, historical and forecasted epidemiology as well as the 7MM market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom),

Myotonic Dystrophy Epidemiology https://www.delveinsight.com/report-store/myotonic-dystrophy-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Myotonic Dystrophy Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Cholangiocarcinoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Latest Reports:

Aneurysmal Subarachnoid Hemorrhage Market https://www.delveinsight.com/report-store/aneurysmal-subarachnoid-hemorrhage-sah-market
DelveInsight's "Aneurysmal Subarachnoid Hemorrhage (SAH) Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Aneurysmal Subarachnoid Hemorrhage (SAH), historical and forecasted epidemiology as well as the Aneurysmal Subarachnoid Hemorrhage (SAH) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Angelman Syndrome Market https://www.delveinsight.com/report-store/angelman-syndrome-market-forecast
DelveInsight's "Angelman Syndrome Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Angelman Syndrome, historical and forecasted epidemiology as well as the Angelman Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.

Autoimmune Pulmonary Alveolar Proteinosis Market https://www.delveinsight.com/report-store/autoimmune-pulmonary-alveolar-proteinosis-apap-market
DelveInsight's "Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Market Insights, Epidemiology and Market Forecast - 2032" report delivers an in-depth understanding of Autoimmune pulmonary alveolar proteinosis, historical and forecasted epidemiology as well as Autoimmune pulmonary alveolar proteinosis market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

Cardiovascular Calcification Market https://www.delveinsight.com/report-store/cardiovascular-calcification-market
DelveInsight's "Cardiovascular Calcification Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Cardiovascular Calcification, historical and forecasted epidemiology as well as the Cardiovascular Calcification market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Charcot Marie Tooth Disease Market https://www.delveinsight.com/report-store/charcot-marie-tooth-disease-market
DelveInsight's 'Charcot-Marie-Tooth Disease Market Insights, Epidemiology, and Market Forecast 2032' report deliver an in-depth understanding of the Charcot-Marie-Tooth Disease, historical and forecasted epidemiology as well as the Charcot-Marie-Tooth Disease market trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.

Contact Us:
Gaurav Bora
gbora@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Myotonic Dystrophy Pipeline Drugs Analysis Report, 2024 Updates: FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight | Dyne Therapeutics, Avidity Biosciences, Harmony Biosciences, AMO Pharma, Lupin, AMO Pharma here

News-ID: 3498137 • Views:

More Releases from DelveInsight Business Research

Heart Failure Pipeline and Clinical Trials Assessment 2024: FDA Approvals, Therapies and Key Companies involved by DelveInsight | Abbott, Berlin Heart GmbH, Biotronik, Boston Scientific Corp, Jarvik Heart Inc., Lepu Medical
Heart Failure Pipeline and Clinical Trials Assessment 2024: FDA Approvals, Thera …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Heart Failure pipeline constitutes 75+ key companies continuously working towards developing 90+ Heart Failure treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight. "Heart Failure Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Heart Failure Market. The Heart
Primary Hyperoxaluria Pipeline and Clinical Trials Assessment: FDA Approvals, Therapies and Key Companies involved by DelveInsight | Alnylam Pharmaceuticals, Inc., Genentech, Inc., Dicerna Pharmaceuticals, Inc., Pfizer Inc., Zhejiang Tianxin Pharmaceutica
Primary Hyperoxaluria Pipeline and Clinical Trials Assessment: FDA Approvals, Th …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Primary Hyperoxaluria pipeline constitutes 8+ key companies continuously working towards developing 8+ Primary Hyperoxaluria treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight. "Primary Hyperoxaluria Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Primary Hyperoxaluria Market. The Primary
Pulmonary Arterial Hypertension Pipeline and Clinical Trials Assessment, 2024 Updates: FDA Approvals, Therapies and Key Companies involved by DelveInsight | Ribomic, Gmax Biopharm LLC., Novartis, Cereno Scientific AB, Insmed Incorporated, Aerovate Therape
Pulmonary Arterial Hypertension Pipeline and Clinical Trials Assessment, 2024 Up …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Pulmonary Arterial Hypertension pipeline constitutes 55+ key companies continuously working towards developing 55+ Pulmonary Arterial Hypertension treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight. "Pulmonary Arterial Hypertension Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Pulmonary Arterial
Endometrial Cancer Pipeline, FDA Approvals, Unmet Needs, Preclinical and Discovery Stage Product, and Companies 2024 (Updated)
Endometrial Cancer Pipeline, FDA Approvals, Unmet Needs, Preclinical and Discove …
DelveInsight's, "Endometrial Cancer Pipeline Insight 2024" report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in Endometrial Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Key Takeaways from the Endometrial Cancer Pipeline Report • DelveInsight's Endometrial Cancer pipeline

All 5 Releases


More Releases for Myotonic

Myotonic Dystrophy Drug Market Size | COVID-19 Impact Analysis | Forecast to 202 …
The global myotonic dystrophy drug market is anticipated to grow at a significant CAGR during the forecast period (2022-2028). Myotonic dystrophy is a muscular dystrophy caused by a long-term genetic mutation. It is the most common type of muscular dystrophy in adulthood, affecting roughly one out of every 8,000 people. Muscle atrophy and weakness worsen over time as a symptom. Muscles contract frequently and take a long time to relax.
Myotonic Muscular Dystrophy Market Size will Observe Substantial Growth by 2027| …
A Muscular dystrophy refers to a group of nine genetic diseases that cause progressive weakness and degeneration of muscles used during voluntary movement. Myotonic dystrophy is one of the muscular dystrophies. It is the most common form seen in adults and is suspected to be among the most common forms overall. Myotonic muscular dystrophy is a common multi-system disorder that affects the skeletal muscles as well as smooth muscles and
Myotonic Dystrophy Drug Market Indeep Research And Detailed Analysis- Lupin, Tev …
MarketInsightsReports, a leading global market research firm, is pleased to announce its new report on Myotonic Dystrophy Drug market, forecast for 2021-2027, covering all aspects of the market and providing up-to-date data on current trends. The Myotonic Dystrophy Drug Market report provides the overall structure and business outlook of the global and regional industries. The study also involves the important Achievements of the market, Research & Development, new product launch, product
Global Myotonic Dystrophy Therapeutics Market Report Forecast to 2027
The report entitled Myotonic Dystrophy Therapeutics Market (2021-2027) Size, Trends and Forecast provides an in-depth analysis of the Myotonic Dystrophy Therapeutics Market including detailed description of market sizing and growth, value, the key opportunities in the Myotonic Dystrophy Therapeutics Market and outlines the factors that are and will be driving the growth of the industry taking into consideration the previous growth patterns. Get sample copy of this report @
Myotonic Dystrophy Drug Market Report Delivering Growth Analysis With Key Trends …
Up Market Research (UMR) offers a detailed report on Global Myotonic Dystrophy Drug Market. The report is a comprehensive research study that provides the scope of Myotonic Dystrophy Drug market size, industry growth opportunities and challenges, current market trends, potential players, and expected performance of the market in regions for the forecast period from 2020 to 2027. This report highlights key insights on the market focusing on the possible requirements
Myotonic Muscular Dystrophy Market: Industry Size, Share, Growth, Forecasts 2017 …
"Myotonic Muscular Dystrophy Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2017 - 2025 " is the latest addition to MarketResearchReports.Biz industry research reports collection. The objectives of this study are as follows: To define, describe, and forecast the "Myotonic Muscular Dystrophy" market by type, application, component, delivery model, end user, and region To provide detailed information regarding major factors influencing market growth (drivers, restraints, opportunities, and industry-specific challenges) To analyze